Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of INCB000631 in Healthy Adults
NCT06775327Phase 1Completed
- Sponsor
- Incyte
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INCB000631 in autoimmune diseases (7 cohorts), sponsored by Incyte. Primary endpoints: Number of participants with Treatment-emergent Adverse Events, Maximum Observed Plasma Concentration and 3 more. Started Feb 2025; status: completed.
02
Drugs
INCB000631
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT06775327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775327.